{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:59:43Z","timestamp":1792789183174,"version":"4.5.0"},"reference-count":36,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T00:00:00Z","timestamp":1790380800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001807","name":"S\u00e3o Paulo Research Foundation","doi-asserted-by":"publisher","award":["2023\/15785-5"],"award-info":[{"award-number":["2023\/15785-5"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001807","name":"S\u00e3o Paulo Research Foundation","doi-asserted-by":"publisher","award":["2022\/12402-5"],"award-info":[{"award-number":["2022\/12402-5"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]},{"award":["2023\/15785-5"],"award-info":[{"award-number":["2023\/15785-5"]}],"id":[{"id":"https:\/\/ror.org\/02ddkpn78","id-type":"ROR","asserted-by":"publisher"}]},{"award":["2022\/12402-5"],"award-info":[{"award-number":["2022\/12402-5"]}],"id":[{"id":"https:\/\/ror.org\/02ddkpn78","id-type":"ROR","asserted-by":"publisher"}]},{"name":"Hospital S\u00edrio-Liban\u00eas","id":[{"id":"https:\/\/ror.org\/03r5mk904","id-type":"ROR","asserted-by":"crossref"}]},{"id":[{"id":"https:\/\/ror.org\/03r5mk904","id-type":"ROR","asserted-by":"publisher"}]},{"name":"Ludwig Institute for Cancer Research","id":[{"id":"https:\/\/ror.org\/05qdwtz81","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background\/Objectives: Combination chemotherapy remains a cornerstone of breast cancer (BC) treatment, yet the relative contribution of individual drugs within standard regimens remains poorly understood. We investigated whether the activity of the widely used anthracycline-cyclophosphamide-taxane (AC-T) regimen reflects uniform benefit from all constituent drugs or heterogeneous drug-specific vulnerabilities across tumors. Methods: We combined in silico drug-response analyses, functional validation in BC cell lines, and ex vivo profiling in patient-derived organoids (PDOs). Drug responses were integrated into the Probability of Chemotherapeutic Efficacy (PCE), a multidimensional response metric combining relative drug potency, maximal efficacy, and clinically achievable free-drug exposure. To explore the broader applicability of PCE, we additionally applied it to an independent publicly available GR-based pharmacological dataset generated by the HMS LINCS Center. Results: Across BC models, anthracyclines and taxanes displayed only partially overlapping sensitivity profiles, indicating distinct drug-specific vulnerabilities. Functional validation in 2D cell lines and PDOs confirmed highly context-dependent responses to AC-T components. Among 21 PDOs with complete drug-response datasets, extensive interpatient heterogeneity was observed, with non-overlapping patterns of sensitivity to A, C, and T. Responses were better represented as a continuum of functional vulnerability states than as binary sensitive-versus-resistant categories. AC generated the highest proportion of favorable response profiles, with 62% of PDOs classified as partial response-like or complete response-like, compared with 48% for A, 38% for C, and 14% for T. AC activity was positively associated with the most active constituent drug within each PDO. Application of this framework to an independent public dataset produced biologically plausible response patterns consistent with the molecular characteristics of the evaluated breast cancer cell lines, supporting its computational transferability. Conclusions: These findings reveal substantial heterogeneity in the contribution of individual drugs to AC-T activity and are compatible with a model in which different tumors derive benefit from different regimen components. Together, these findings establish a hypothesis-generating functional framework for dissecting the contribution of individual drugs within combination chemotherapy regimens. Prospective studies correlating PDO-derived functional responses with clinical outcomes will be required to determine the predictive value and potential clinical utility of this approach before informing therapeutic decision-making.<\/jats:p>","DOI":"10.3390\/cancers18193121","type":"journal-article","created":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T10:00:34Z","timestamp":1790589634000},"page":"3121","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Functional Deconstruction of AC-T Chemotherapy Reveals Interindividual Heterogeneity and Independent Drug Action in Breast Cancer"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7694-7370","authenticated-orcid":false,"given":"Lucas Dam\u00e9","family":"Sim\u00f5es","sequence":"first","affiliation":[{"name":"Molecular Oncology Center, Hospital S\u00edrio-Liban\u00eas, S\u00e3o Paulo 01308-060, SP, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"investigation","vocabulary":"credit"},{"role":"methodology","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"}]},{"given":"Giulia Luiza","family":"Santos","sequence":"additional","affiliation":[{"name":"Molecular Oncology Center, Hospital S\u00edrio-Liban\u00eas, S\u00e3o Paulo 01308-060, SP, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"methodology","vocabulary":"credit"},{"role":"investigation","vocabulary":"credit"}]},{"given":"Priscila Oliveira de","family":"Carvalho","sequence":"additional","affiliation":[{"name":"Molecular Oncology Center, Hospital S\u00edrio-Liban\u00eas, S\u00e3o Paulo 01308-060, SP, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"investigation","vocabulary":"credit"},{"role":"methodology","vocabulary":"credit"}]},{"given":"Ernande Xavier dos","family":"Santos","sequence":"additional","affiliation":[{"name":"Molecular Oncology Center, Hospital S\u00edrio-Liban\u00eas, S\u00e3o Paulo 01308-060, SP, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"methodology","vocabulary":"credit"}]},{"given":"Amanda Rafaela Alves","family":"Canteli","sequence":"additional","affiliation":[{"name":"Molecular Oncology Center, Hospital S\u00edrio-Liban\u00eas, S\u00e3o Paulo 01308-060, SP, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronaldo","family":"Morales Junior","sequence":"additional","affiliation":[{"name":"Molecular Oncology Center, Hospital S\u00edrio-Liban\u00eas, S\u00e3o Paulo 01308-060, SP, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina Rossi","family":"Saccarelli","sequence":"additional","affiliation":[{"name":"N\u00facleo de Diagn\u00f3stico por Imagem da Mama, Hospital S\u00edrio-Liban\u00eas, S\u00e3o Paulo 01308-060, SP, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"investigation","vocabulary":"credit"},{"role":"methodology","vocabulary":"credit"}]},{"given":"Larissa Assad Jo\u00e3o","family":"Moys\u00e9s","sequence":"additional","affiliation":[{"name":"N\u00facleo de Diagn\u00f3stico por Imagem da Mama, Hospital S\u00edrio-Liban\u00eas, S\u00e3o Paulo 01308-060, SP, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"investigation","vocabulary":"credit"},{"role":"methodology","vocabulary":"credit"}]},{"given":"Ligia Akemi","family":"Yamashita","sequence":"additional","affiliation":[{"name":"N\u00facleo de Diagn\u00f3stico por Imagem da Mama, Hospital S\u00edrio-Liban\u00eas, S\u00e3o Paulo 01308-060, SP, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"investigation","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7136-3875","authenticated-orcid":false,"given":"Patricia","family":"Akissue de Camargo Teixeira","sequence":"additional","affiliation":[{"name":"N\u00facleo de Diagn\u00f3stico por Imagem da Mama, Hospital S\u00edrio-Liban\u00eas, S\u00e3o Paulo 01308-060, SP, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"investigation","vocabulary":"credit"},{"role":"methodology","vocabulary":"credit"}]},{"given":"Thiago Yoshio","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"N\u00facleo de Diagn\u00f3stico por Imagem da Mama, Hospital S\u00edrio-Liban\u00eas, S\u00e3o Paulo 01308-060, SP, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"investigation","vocabulary":"credit"}]},{"given":"Vera Christina Camargo de Siqueira","family":"Ferreira","sequence":"additional","affiliation":[{"name":"N\u00facleo de Diagn\u00f3stico por Imagem da Mama, Hospital S\u00edrio-Liban\u00eas, S\u00e3o Paulo 01308-060, SP, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"investigation","vocabulary":"credit"},{"role":"methodology","vocabulary":"credit"}]},{"given":"Vivian Larissa Nakamura","family":"Omura","sequence":"additional","affiliation":[{"name":"N\u00facleo de Diagn\u00f3stico por Imagem da Mama, Hospital S\u00edrio-Liban\u00eas, S\u00e3o Paulo 01308-060, SP, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"investigation","vocabulary":"credit"},{"role":"methodology","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-2685-604X","authenticated-orcid":false,"given":"Luma Soares de","family":"Almeida","sequence":"additional","affiliation":[{"name":"Molecular Oncology Center, Hospital S\u00edrio-Liban\u00eas, S\u00e3o Paulo 01308-060, SP, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"investigation","vocabulary":"credit"},{"role":"methodology","vocabulary":"credit"}]},{"given":"Carlos Henrique dos","family":"Anjos","sequence":"additional","affiliation":[{"name":"Molecular Oncology Center, Hospital S\u00edrio-Liban\u00eas, S\u00e3o Paulo 01308-060, SP, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo Carlos S. D. de","family":"Barros","sequence":"additional","affiliation":[{"name":"Department of Oncology, Hospital S\u00edrio-Liban\u00eas, S\u00e3o Paulo 01308-060, SP, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anamaria Aranha","family":"Camargo","sequence":"additional","affiliation":[{"name":"Molecular Oncology Center, Hospital S\u00edrio-Liban\u00eas, S\u00e3o Paulo 01308-060, SP, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"funding-acquisition","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3052-4062","authenticated-orcid":false,"given":"Jos\u00e9 Luiz B.","family":"Bevilacqua","sequence":"additional","affiliation":[{"name":"N\u00facleo de Mastologia, Hospital S\u00edrio-Liban\u00eas, S\u00e3o Paulo 01308-060, SP, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"conceptualization","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"},{"role":"funding-acquisition","vocabulary":"credit"}]},{"given":"Daniela G.","family":"Giannotti","sequence":"additional","affiliation":[{"name":"N\u00facleo de Diagn\u00f3stico por Imagem da Mama, Hospital S\u00edrio-Liban\u00eas, S\u00e3o Paulo 01308-060, SP, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"conceptualization","vocabulary":"credit"},{"role":"supervision","vocabulary":"credit"},{"role":"investigation","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7413-4675","authenticated-orcid":false,"given":"\u00c9rico Tosoni","family":"Costa","sequence":"additional","affiliation":[{"name":"Molecular Oncology Center, Hospital S\u00edrio-Liban\u00eas, S\u00e3o Paulo 01308-060, SP, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"conceptualization","vocabulary":"credit"},{"role":"formal-analysis","vocabulary":"credit"},{"role":"writing-original-draft","vocabulary":"credit"},{"role":"project-administration","vocabulary":"credit"},{"role":"investigation","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"},{"role":"funding-acquisition","vocabulary":"credit"},{"role":"resources","vocabulary":"credit"},{"role":"data-curation","vocabulary":"credit"},{"role":"supervision","vocabulary":"credit"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/S0140-6736(16)31891-8","article-title":"Breast cancer","volume":"389","author":"Harbeck","year":"2017","journal-title":"Lancet"},{"key":"ref_2","first-page":"7","article-title":"Cancer statistics, 2017","volume":"67","author":"Siegel","year":"2017","journal-title":"CA Cancer J. Clin."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/35021093","article-title":"Molecular portraits of human breast tumours","volume":"406","author":"Perou","year":"2000","journal-title":"Nature"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"10869","DOI":"10.1073\/pnas.191367098","article-title":"Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications","volume":"98","author":"Perou","year":"2001","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1038\/s41416-021-01328-7","article-title":"Breast cancer as an example of tumour heterogeneity and tumour cell plasticity during malignant progression","volume":"125","author":"Tiede","year":"2021","journal-title":"Br. J. Cancer"},{"key":"ref_6","first-page":"721","article-title":"Breast cancer: An overview of current therapeutic strategies, challenges, and perspectives","volume":"15","author":"Wang","year":"2023","journal-title":"Breast Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/nbt.2284","article-title":"Combinatorial drug therapy for cancer in the post-genomic era","volume":"30","author":"Banerji","year":"2012","journal-title":"Nat. Biotechnol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1200\/JCO.2008.19.2567","article-title":"Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer","volume":"27","author":"Gianni","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1158\/2159-8290.CD-21-0212","article-title":"Independent drug action in combination therapy: Implications for precision oncology","volume":"12","author":"Plana","year":"2022","journal-title":"Cancer Discov."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/s41586-022-04437-2","article-title":"Effective drug combinations in breast, colon and pancreatic cancer cells","volume":"603","author":"Jaaks","year":"2022","journal-title":"Nature"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1186\/s12935-024-03375-5","article-title":"Breast cancer patient-derived organoids for the investigation of patient-specific tumour evolution","volume":"24","author":"Mazzucchelli","year":"2024","journal-title":"Cancer Cell Int."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Policastro, B., Nissen, N., and Alves, C.L. (2025). Deciphering breast tumor heterogeneity through patient-derived organoids and circulating tumor cells. J. Pers. Med., 15.","DOI":"10.3390\/jpm15070271"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1126\/science.aao2774","article-title":"Patient-derived organoids model treatment response of metastatic gastrointestinal cancers","volume":"359","author":"Vlachogiannis","year":"2018","journal-title":"Science"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1158\/2159-8290.CD-18-0349","article-title":"Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer","volume":"8","author":"Tiriac","year":"2018","journal-title":"Cancer Discov."},{"key":"ref_15","first-page":"26","article-title":"Tumor organoids: Breakthroughs in clinical decision making, drug development, and translational advances beyond conventional models","volume":"2","author":"Wu","year":"2026","journal-title":"Med. Res."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Shi, Y., Guan, Z., Cai, G., Nie, Y., Zhang, C., Luo, W., and Liu, J. (2024). Patient-derived organoids: A promising tool for breast cancer research. Front. Oncol., 14.","DOI":"10.3389\/fonc.2024.1350935"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.cell.2017.11.010","article-title":"A living biobank of breast cancer organoids captures disease heterogeneity","volume":"172","author":"Sachs","year":"2018","journal-title":"Cell"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e2101176","DOI":"10.1002\/advs.202101176","article-title":"Patient-derived organoids can guide personalized therapies for patients with advanced breast cancer","volume":"8","author":"Chen","year":"2021","journal-title":"Adv. Sci."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"4238","DOI":"10.1038\/s41467-026-72903-w","article-title":"Critical evaluation of drug response prediction models with DrEval","volume":"17","author":"Bernett","year":"2026","journal-title":"Nat. Commun."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/nmeth.3853","article-title":"Growth rate inhibition metrics correct for confounders in measuring sensitivity to cancer drugs","volume":"13","author":"Hafner","year":"2016","journal-title":"Nat. Methods"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/s41580-026-00974-0","article-title":"New developments and applications of human organoids","volume":"27","author":"Clevers","year":"2026","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"D955","DOI":"10.1093\/nar\/gks1111","article-title":"Genomics of Drug Sensitivity in Cancer (GDSC): A resource for therapeutic biomarker discovery in cancer cells","volume":"41","author":"Yang","year":"2013","journal-title":"Nucleic Acids Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.1158\/1078-0432.CCR-16-3083","article-title":"Clinically relevant concentrations of anticancer drugs: A guide for nonclinical studies","volume":"23","author":"Liston","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Fournier, L., de Geus-Oei, L.F., Regge, D., Oprea-Lager, D.E., D\u2019Anastasi, M., Bidaut, L., B\u00e4uerle, T., Lopci, E., Cappello, G., and Lecouvet, F. (2022). Twenty years on: RECIST as a biomarker of response in solid tumours an EORTC Imaging Group-ESOI joint paper. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.800547"},{"key":"ref_25","unstructured":"HMS LINCS Center, and Broad Institute LINCS Center for Transcriptomics (2026, July 01). HMS LINCS Datasets #20245\u201320251: Growth Rate (GR) Dose\u2013Response Metrics for Breast Cancer Cell Lines. LINCS Data Portal, Available online: https:\/\/lincsproject.org\/LINCS\/data."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.canlet.2012.01.039","article-title":"Dasatinib synergizes with both cytotoxic and signal transduction inhibitors in heterogeneous breast cancer cell lines--lessons for design of combination targeted therapy","volume":"320","author":"Park","year":"2012","journal-title":"Cancer Lett."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"412","DOI":"10.5306\/wjco.v5.i3.412","article-title":"Biological subtypes of breast cancer: Prognostic and therapeutic implications","volume":"5","author":"Yersal","year":"2014","journal-title":"World J. Clin. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1016\/S0140-6736(24)00054-0","article-title":"3-year invasive disease-free survival with chemotherapy de-escalation using an 18F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): A randomised, open-label, phase 2 trial","volume":"403","author":"Colleoni","year":"2024","journal-title":"Lancet"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S1470-2045(24)00104-9","article-title":"MRI-guided optimisation of neoadjuvant chemotherapy duration in stage II\u2013III HER2-positive breast cancer (TRAIN-3): A multicentre, single-arm, phase 2 study","volume":"25","author":"Louis","year":"2024","journal-title":"Lancet Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/s13058-025-02070-1","article-title":"Combined prognostic impact of initial clinical stage and residual cancer burden after neoadjuvant systemic therapy in triple-negative and HER2-positive breast cancer: An analysis of the I-SPY2 randomized clinical trial","volume":"27","author":"Dimitroff","year":"2025","journal-title":"Breast Cancer Res."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Zhao, R., Feng, Q., Xia, Y., Liao, L., and Xie, S. (2025). Iteration of Tumor Organoids in Drug Development: Simplification and Integration. Pharmaceuticals, 18.","DOI":"10.3390\/ph18101540"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1186\/s12967-026-08107-z","article-title":"Modeling metastasis and predicting drug response with malignant effusion-derived organoids: A systematic review and quantitative assessment","volume":"24","author":"Peng","year":"2026","journal-title":"J. Transl. Med."},{"key":"ref_33","unstructured":"K2 Oncology, Inc. (2026, June 30). Drug Sensitivity Correlation Between Patient-Derived Organoid Model and Clinical Response in NSCLC Patients. ClinicalTrials.gov Identifier: NCT03453307, Available online: https:\/\/clinicaltrials.gov\/study\/NCT03453307."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"45745","DOI":"10.18632\/oncotarget.9935","article-title":"The relevance of using 3D cell cultures, in addition to 2D monolayer cultures, when evaluating breast cancer drug sensitivity and resistance","volume":"7","author":"Breslin","year":"2016","journal-title":"Oncotarget"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1038\/modpathol.2011.172","article-title":"Aldehyde dehydrogenase 1A1 expression in breast cancer is associated with stage, triple negativity, and outcome to neoadjuvant chemotherapy","volume":"25","author":"Khoury","year":"2012","journal-title":"Mod. Pathol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/s13568-020-01064-w","article-title":"Synthesis of cyclophosphamide metabolites by a peroxygenase from Marasmius rotula for toxicological studies on human cancer cells","volume":"10","author":"Steinbrecht","year":"2020","journal-title":"AMB Express."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/19\/3121\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T04:16:58Z","timestamp":1790655418000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/19\/3121"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,26]]},"references-count":36,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["cancers18193121"],"URL":"https:\/\/doi.org\/10.3390\/cancers18193121","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,26]]}}}